Remove Biotechnology Remove Development Remove Licensing
article thumbnail

Cyrus Biotech spins out company to expand reach of versatile drug development software

GeekWire

Levitate Bio’s CEO Sam DeLuca, left, and Karen Khar, executive vice president of sales and business development. The University of Washington has issued more than 60,000 non-commercial licenses to Rosetta users, and more than 200 licenses to commercial organizations. Tech companies are really good at what they do.

Software 112
article thumbnail

Mars Society gains foothold in AI, robotics and biotechnology to clear a path to space

GeekWire

To make a profit, yes, but also to support the development of technologies needed to sustain settlements on the Red Planet. “Those inventions — as it were, IP as exports from Mars — will be one of the main economic supports of the Mars city-state,” Zubrin said.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics

GeekWire

Sana Biotechnology has a new $50 million tool in its toolbox. Beam may also receive additional payments, for instance upon the achievement of development and sales milestones. Sana aims to develop therapeutics for conditions as diverse as cancer, diabetes and cardiovascular disorders. Sana CEO and president Steve Harr.

article thumbnail

Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch

GeekWire

Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. The company, a spin-out from the UW’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. Icosavax Photo).

article thumbnail

Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M

GeekWire

Seattle-based cell therapy startup Immusoft will collaborate with pharma giant Takeda to develop treatments targeted to the central nervous system in a deal worth potentially more than $900 million. Immusoft CEO Sean Ainsworth. Immusoft Photo). Immusoft closed a $33 million Series B round last year, noted FierceBiotech.

article thumbnail

Merck’s multi-billion dollar bet on Seattle Genetics sparks hope for breast cancer treatments

GeekWire

based biotechnology company struck a deal with Merck in which the pharmaceutical powerhouse will provide a $600 million upfront payment and make a $1 billion equity investment to continue development of treatments for breast cancer. billion if development milestones are met, and another $1.75 Merck will own about 2.9

article thumbnail

Shares of Neoleukin Therapeutics spike after announcing layoffs and potential sale or merger

GeekWire

The publicly traded Seattle biotech company hired investment bank SVB Securities to review potential alternatives including a sale, merger, asset divestiture or licensing. “It Neoleukin shifted its focus to developing other protein therapeutics.